MedTrace Logo

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

NCT03868839 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-03-02

Study results available
· View outcomes & findings →

Summary

This study is a 4-week pilot study for subjects with Schizophrenia or Schizoaffective Disorder who have not experienced a significant relief of symptoms from current anti-psychotic medication. The Investigators hypothesize that 4 weeks of telmisartan at 80mg daily will alter blood biomarkers for inflammation and oxidative stress after 4 weeks treatment.

Conditions

  • Schizophrenia
  • Schizo Affective Disorder
  • Treatment-resistant Schizophrenia

Interventions

DRUG

Telmisartan Pill

telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.

Sponsors & Collaborators

  • Xiaoduo Fan

    lead OTHER

Principal Investigators

  • Xiaoduo Fan, MD, MPH · University of Massachusetts, Worcester

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-10-07
Completion
2020-10-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03868839 on ClinicalTrials.gov